Search

Your search keyword '"Saito, K."' showing total 778 results

Search Constraints

Start Over You searched for: Author "Saito, K." Remove constraint Author: "Saito, K." Publisher elsevier bv Remove constraint Publisher: elsevier bv
778 results on '"Saito, K."'

Search Results

1. Real-world outcomes of first-line systematic treatment in advanced upper urinary tract urothelial carcinoma patients with renal impairment: YUSHIMA-04 study

2. Outcomes of partial and radical nephrectomy in patients with pathological T3a upstaging of clinical T1 renal cell carcinoma: an analysis from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort

8. Impact of preoperative C-reactive protein level on oncological outcomes after nephrectomy in patients with high-risk renal cell carcinoma: An analysis from the International Marker Consortium for Renal Cancer (INMARC) cohort

9. Test and extraction methods for the QC parameters of silicon strip sensors for ATLAS upgrade tracker

12. 142P The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE

13. 144P Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab

14. 139MO Prognostic significance of the mechanism of inflammatory markers in advanced renal cell carcinoma patients treated with nivolumab plus ipilimumab

16. P.103 Onasemnogene abeparvovec (OA) treatment outcomes by patient weight at infusion: Initial findings from the RESTORE registry

18. P.114 SUNFISH parts 1 and 2: 3-year efficacy and safety of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)

19. P.104 Treatments and outcomes for patients with spinal muscular atrophy (SMA) type 2: Findings from RESTORE registry

20. P.105 Safety and effectiveness of onasemnogene abeparvovec (OA) alone or with other disease-modifying therapies (DMTs): Findings from RESTORE

22. Disparities in cancer-specific mortality between Asian and Caucasian patients with non-metastatic renal cell carcinoma: Analysis of the INMARC registry

27. 68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis

29. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting

30. SMA - TREATMENT

31. SMA - TREATMENT

32. SMA CLINICAL DATA

33. P41.02 Surgery for Small Pulmonary NUT Carcinoma: Case Report

34. SMA - TREATMENT

35. O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma

39. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry

44. Charge collection study with the ATLAS ITk prototype silicon strip sensors ATLAS17LS

46. SMA – THERAPY

47. SMA: REGISTRIES, BIOMARKERS & OUTCOME MEASURES

48. SMA – THERAPY

49. SMA – THERAPY

50. 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study

Catalog

Books, media, physical & digital resources